---
title: "Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis [Research]"
id: "cmaj-0-cardiovascular-and-renal-outcomes-of-combined-sglt2-inhibitors-and-glp-1"
canonical_url: "https://medichelpline.com/clinical-feed/cmaj-0-cardiovascular-and-renal-outcomes-of-combined-sglt2-inhibitors-and-glp-1"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "CMAJ"
source_url: "http://www.cmaj.ca/cgi/content/short/198/26/E992?rss=1"
published_at: "2026-07-13T04:05:21.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis [Research]
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/cmaj-0-cardiovascular-and-renal-outcomes-of-combined-sglt2-inhibitors-and-glp-1
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** CMAJ
- **Source URL:** [Original Journal Publication](http://www.cmaj.ca/cgi/content/short/198/26/E992?rss=1)
- **Published At:** 2026-07-13T04:05:21.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Background: Whether using both sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is more effective than using either alone in type 2 diabetes mellitus remains uncertain. We sought to assess cardiovascular and kidney outcomes of combined SGLT2i and GLP-1RA therapy versus monotherapy using network meta-analysis. Methods: We identified randomized controlled trials (RCTs) of SGLT2i or GLP-1RA in patients with type 2 diabetes mellitus through a comprehensive search of MEDLINE, Embase, and the Cochrane Library until Aug. 15, 2025. We compared patients receiving SGLT2i, GLP-1RA, both SGLT2i and GLP-1RA, or neither medication in a systematic review and network meta-analysis. Primary outcomes were major adverse cardiovascular events (cardiovascular death, myocardial infarction, and stroke) and major adverse kidney events (decline in estimated glomerular filtration rate, kidney failure, and death due to kidney failure). Secondary outcomes included heart failure–related hospital admissions, serious adverse events, and hypoglycemia. Results: We included 12 RCTs with 99 683 participants.
## Clinical Analysis & Structured Key Points
CMAJ published a clinical update in Research Highlights on 13 Jul 2026. The item focuses on Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis [Research]. Review the original article for the full source wording and details.
## Related Clinical Research

- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)
- [7 am May Be a Sweet Spot for Workouts to Lower Cardiometabolic Risk](https://medichelpline.com/clinical-feed/medical-news-today-22-7-am-may-be-sweet-spot-for-workouts-to-lower-cardiometabolic-risk.md)
- [Multimodal extraction of heart disease risk factors from free-text and structured records using Li](https://medichelpline.com/clinical-feed/plos-one-0-leveraging-free-text-clinical-records-for-heart-disease-classification-through.md)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.